Trial Outcomes & Findings for A Randomized Trial of Interim Methadone and Patient Navigation Initiated in Jail (NCT NCT02334215)
NCT ID: NCT02334215
Last Updated: 2020-09-16
Results Overview
Predicted probability derived from the generalized linear mixed model opioid positive urine tests (0= negative; 1- positive) for heroin, oxycodone, methadone, or buprenorphine -- excluding the latter two positives when they results from prescribed medications to treat opioid use disorder)
Recruitment status
COMPLETED
Study phase
NA
Target enrollment
225 participants
Primary outcome timeframe
1, 3, 6, and 12 months post-release from incarceration
Results posted on
2020-09-16
Participant Flow
Participant milestones
| Measure |
Methadone Plus Patient Navigation
Participants will begin methadone treatment during detention and will have a patient navigator for up to 3 months post-release from detention.
Methadone: Interim methadone treatment (methadone without routine counseling) will be provided in jail. Methadone treatment with counseling will be continued in the community.
Patient Navigation: A patient navigator will assist the participant for the first three months after release from jail to enter and remain in methadone treatment in the community.
|
Methadone
Participants will begin methadone during detention.
Methadone: Interim methadone treatment (methadone without routine counseling) will be provided in jail. Methadone treatment with counseling will be continued in the community.
|
Enhanced Treatment as Usual
Participants will receive opioid detoxification during detention, as well as drug abuse education, overdose prevention education, and referral to drug abuse treatment and overdose prevention services in the community.
Enhanced Treatment as Usual (ETAU): Participants will receive methadone detoxification, drug abuse and overdose prevention information, drug treatment and overdose prevention referral in the community.
|
|---|---|---|---|
|
Overall Study
STARTED
|
75
|
74
|
76
|
|
Overall Study
COMPLETED
|
68
|
68
|
61
|
|
Overall Study
NOT COMPLETED
|
7
|
6
|
15
|
Reasons for withdrawal
| Measure |
Methadone Plus Patient Navigation
Participants will begin methadone treatment during detention and will have a patient navigator for up to 3 months post-release from detention.
Methadone: Interim methadone treatment (methadone without routine counseling) will be provided in jail. Methadone treatment with counseling will be continued in the community.
Patient Navigation: A patient navigator will assist the participant for the first three months after release from jail to enter and remain in methadone treatment in the community.
|
Methadone
Participants will begin methadone during detention.
Methadone: Interim methadone treatment (methadone without routine counseling) will be provided in jail. Methadone treatment with counseling will be continued in the community.
|
Enhanced Treatment as Usual
Participants will receive opioid detoxification during detention, as well as drug abuse education, overdose prevention education, and referral to drug abuse treatment and overdose prevention services in the community.
Enhanced Treatment as Usual (ETAU): Participants will receive methadone detoxification, drug abuse and overdose prevention information, drug treatment and overdose prevention referral in the community.
|
|---|---|---|---|
|
Overall Study
Death
|
1
|
1
|
0
|
|
Overall Study
Lost to Follow-up
|
1
|
0
|
4
|
|
Overall Study
Withdrawal by Subject
|
2
|
2
|
1
|
|
Overall Study
Not released from incarceration on time
|
3
|
3
|
3
|
|
Overall Study
Incarcerated
|
0
|
0
|
7
|
Baseline Characteristics
A Randomized Trial of Interim Methadone and Patient Navigation Initiated in Jail
Baseline characteristics by cohort
| Measure |
Methadone Plus Patient Navigation
n=75 Participants
Participants will begin methadone treatment during detention and will have a patient navigator for up to 3 months post-release from detention.
Methadone: Interim methadone treatment (methadone without routine counseling) will be provided in jail. Methadone treatment with counseling will be continued in the community.
Patient Navigation: A patient navigator will assist the participant for the first three months after release from jail to enter and remain in methadone treatment in the community.
|
Methadone
n=74 Participants
Participants will begin methadone during detention.
Methadone: Interim methadone treatment (methadone without routine counseling) will be provided in jail. Methadone treatment with counseling will be continued in the community.
|
Enhanced Treatment as Usual
n=76 Participants
Participants will receive opioid detoxification during detention, as well as drug abuse education, overdose prevention education, and referral to drug abuse treatment and overdose prevention services in the community.
Enhanced Treatment as Usual (ETAU): Participants will receive methadone detoxification, drug abuse and overdose prevention information, drug treatment and overdose prevention referral in the community.
|
Total
n=225 Participants
Total of all reporting groups
|
|---|---|---|---|---|
|
Age, Continuous
|
39.6 years
STANDARD_DEVIATION 10.0 • n=5 Participants
|
37.3 years
STANDARD_DEVIATION 10.0 • n=7 Participants
|
37.9 years
STANDARD_DEVIATION 11.1 • n=5 Participants
|
38.3 years
STANDARD_DEVIATION 10.4 • n=4 Participants
|
|
Sex: Female, Male
Female
|
15 Participants
n=5 Participants
|
14 Participants
n=7 Participants
|
15 Participants
n=5 Participants
|
44 Participants
n=4 Participants
|
|
Sex: Female, Male
Male
|
60 Participants
n=5 Participants
|
60 Participants
n=7 Participants
|
61 Participants
n=5 Participants
|
181 Participants
n=4 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
3 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
3 Participants
n=5 Participants
|
6 Participants
n=4 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
72 Participants
n=5 Participants
|
74 Participants
n=7 Participants
|
73 Participants
n=5 Participants
|
219 Participants
n=4 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
|
Race (NIH/OMB)
Black or African American
|
51 Participants
n=5 Participants
|
45 Participants
n=7 Participants
|
43 Participants
n=5 Participants
|
139 Participants
n=4 Participants
|
|
Race (NIH/OMB)
White
|
17 Participants
n=5 Participants
|
17 Participants
n=7 Participants
|
22 Participants
n=5 Participants
|
56 Participants
n=4 Participants
|
|
Race (NIH/OMB)
More than one race
|
6 Participants
n=5 Participants
|
12 Participants
n=7 Participants
|
9 Participants
n=5 Participants
|
27 Participants
n=4 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
1 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
2 Participants
n=5 Participants
|
3 Participants
n=4 Participants
|
|
Region of Enrollment
United States
|
75 Participants
n=5 Participants
|
74 Participants
n=7 Participants
|
76 Participants
n=5 Participants
|
225 Participants
n=4 Participants
|
PRIMARY outcome
Timeframe: 1, 3, 6, and 12 months post-release from incarcerationPopulation: The number analyzed at the follow-up points differ due to missing data (e.g., lost to follow-up, incarcerated individuals who were not drug tested, people interviewed by phone because they no longer lived in the area).
Predicted probability derived from the generalized linear mixed model opioid positive urine tests (0= negative; 1- positive) for heroin, oxycodone, methadone, or buprenorphine -- excluding the latter two positives when they results from prescribed medications to treat opioid use disorder)
Outcome measures
| Measure |
Methadone Plus Patient Navigation
n=68 Participants
Participants will begin methadone treatment during detention and will have a patient navigator for up to 3 months post-release from detention.
Methadone: Interim methadone treatment (methadone without routine counseling) will be provided in jail. Methadone treatment with counseling will be continued in the community.
Patient Navigation: A patient navigator will assist the participant for the first three months after release from jail to enter and remain in methadone treatment in the community.
|
Methadone
n=68 Participants
Participants will begin methadone during detention.
Methadone: Interim methadone treatment (methadone without routine counseling) will be provided in jail. Methadone treatment with counseling will be continued in the community.
|
Enhanced Treatment as Usual
n=61 Participants
Participants will receive opioid detoxification during detention, as well as drug abuse education, overdose prevention education, and referral to drug abuse treatment and overdose prevention services in the community.
Enhanced Treatment as Usual (ETAU): Participants will receive methadone detoxification, drug abuse and overdose prevention information, drug treatment and overdose prevention referral in the community.
|
|---|---|---|---|
|
Predicted Probability Derived From the Generalized Linear Mixed Model of Opioid Urine Test Positive Results Over Time
1 month post-release from incarceration
|
0.70 Probability
Standard Error 0.08
|
0.72 Probability
Standard Error 0.09
|
0.66 Probability
Standard Error 0.09
|
|
Predicted Probability Derived From the Generalized Linear Mixed Model of Opioid Urine Test Positive Results Over Time
3 months post-release from incarceration
|
0.59 Probability
Standard Error 0.08
|
0.72 Probability
Standard Error 0.09
|
0.73 Probability
Standard Error 0.08
|
|
Predicted Probability Derived From the Generalized Linear Mixed Model of Opioid Urine Test Positive Results Over Time
6 months post-release from incarceration
|
0.49 Probability
Standard Error 0.09
|
0.63 Probability
Standard Error 0.10
|
0.71 Probability
Standard Error 0.08
|
|
Predicted Probability Derived From the Generalized Linear Mixed Model of Opioid Urine Test Positive Results Over Time
12 months post-release from incarceration
|
0.46 Probability
Standard Error 0.08
|
0.71 Probability
Standard Error 0.09
|
0.59 Probability
Standard Error 0.09
|
PRIMARY outcome
Timeframe: 30 days post-release from incarcerationPredicted probability derived from the general linear mixed model of self-reported entry into treatment for opioid use disorder following release from incarceration and being in treatment 30 days post-release (0= no entry in treatment; 1= entry in treatment).
Outcome measures
| Measure |
Methadone Plus Patient Navigation
n=61 Participants
Participants will begin methadone treatment during detention and will have a patient navigator for up to 3 months post-release from detention.
Methadone: Interim methadone treatment (methadone without routine counseling) will be provided in jail. Methadone treatment with counseling will be continued in the community.
Patient Navigation: A patient navigator will assist the participant for the first three months after release from jail to enter and remain in methadone treatment in the community.
|
Methadone
n=56 Participants
Participants will begin methadone during detention.
Methadone: Interim methadone treatment (methadone without routine counseling) will be provided in jail. Methadone treatment with counseling will be continued in the community.
|
Enhanced Treatment as Usual
n=50 Participants
Participants will receive opioid detoxification during detention, as well as drug abuse education, overdose prevention education, and referral to drug abuse treatment and overdose prevention services in the community.
Enhanced Treatment as Usual (ETAU): Participants will receive methadone detoxification, drug abuse and overdose prevention information, drug treatment and overdose prevention referral in the community.
|
|---|---|---|---|
|
Predicted Probability Derived From the General Linear Mixed Model of Entry Into Treatment for Opioid Use Disorder on the Methadone Treatment Exposure Form
|
0.65 Probability
Standard Error 0.09
|
0.62 Probability
Standard Error 0.10
|
0.225 Probability
Standard Error 0.09
|
SECONDARY outcome
Timeframe: one month period prior to the 3, 6, and 12 month post-release from incarcerationPopulation: The number analyzed at the follow-up points differ due to missing data (e.g., lost to follow-up, people who were incarcerated during the 30 days prior to the interview).
Predicted probability derived from the Generalized Linear Mixed Model of meeting the Data and Statistical Manual - 5 criteria for Opioid Use Disorder in response to modified CIDI interview (0= does not meet criteria; 1= meets criteria).
Outcome measures
| Measure |
Methadone Plus Patient Navigation
n=67 Participants
Participants will begin methadone treatment during detention and will have a patient navigator for up to 3 months post-release from detention.
Methadone: Interim methadone treatment (methadone without routine counseling) will be provided in jail. Methadone treatment with counseling will be continued in the community.
Patient Navigation: A patient navigator will assist the participant for the first three months after release from jail to enter and remain in methadone treatment in the community.
|
Methadone
n=68 Participants
Participants will begin methadone during detention.
Methadone: Interim methadone treatment (methadone without routine counseling) will be provided in jail. Methadone treatment with counseling will be continued in the community.
|
Enhanced Treatment as Usual
n=68 Participants
Participants will receive opioid detoxification during detention, as well as drug abuse education, overdose prevention education, and referral to drug abuse treatment and overdose prevention services in the community.
Enhanced Treatment as Usual (ETAU): Participants will receive methadone detoxification, drug abuse and overdose prevention information, drug treatment and overdose prevention referral in the community.
|
|---|---|---|---|
|
Predicted Probability Derived From Generalized Linear Mixed Model of Meeting Opioid Use Disorder Criteria as Determined by the Modified Composite International Diagnostic Interview (CIDI)
3 months post-release from incarceration
|
0.66 Probability
Standard Error 0.09
|
0.70 Probability
Standard Error 0.08
|
0.76 Probability
Standard Error 0.08
|
|
Predicted Probability Derived From Generalized Linear Mixed Model of Meeting Opioid Use Disorder Criteria as Determined by the Modified Composite International Diagnostic Interview (CIDI)
6 months post-release from incarceration
|
0.51 Probability
Standard Error 0.09
|
0.59 Probability
Standard Error 0.09
|
0.77 Probability
Standard Error 0.08
|
|
Predicted Probability Derived From Generalized Linear Mixed Model of Meeting Opioid Use Disorder Criteria as Determined by the Modified Composite International Diagnostic Interview (CIDI)
12 months post-release from incarceration
|
0.54 Probability
Standard Error 0.09
|
0.77 Probability
Standard Error 0.11
|
0.59 Probability
Standard Error 0.09
|
SECONDARY outcome
Timeframe: one year post-release from incarcerationPopulation: Data presented on the subset of those participants who were released from index incarceration during the study.
Official data on participant arrests subsequent to release from index incarceration.
Outcome measures
| Measure |
Methadone Plus Patient Navigation
n=71 Participants
Participants will begin methadone treatment during detention and will have a patient navigator for up to 3 months post-release from detention.
Methadone: Interim methadone treatment (methadone without routine counseling) will be provided in jail. Methadone treatment with counseling will be continued in the community.
Patient Navigation: A patient navigator will assist the participant for the first three months after release from jail to enter and remain in methadone treatment in the community.
|
Methadone
n=69 Participants
Participants will begin methadone during detention.
Methadone: Interim methadone treatment (methadone without routine counseling) will be provided in jail. Methadone treatment with counseling will be continued in the community.
|
Enhanced Treatment as Usual
n=72 Participants
Participants will receive opioid detoxification during detention, as well as drug abuse education, overdose prevention education, and referral to drug abuse treatment and overdose prevention services in the community.
Enhanced Treatment as Usual (ETAU): Participants will receive methadone detoxification, drug abuse and overdose prevention information, drug treatment and overdose prevention referral in the community.
|
|---|---|---|---|
|
Number of Participants With Arrests
|
32 Participants
|
39 Participants
|
36 Participants
|
SECONDARY outcome
Timeframe: Baseline and 6, and 12 months post-release from incarcerationPopulation: The number analyzed at the follow-up points differ due to missing data (e.g., lost to follow-up, people who were incarcerated during the 6 months prior to the interview).
Drug Risk Scale Score on the Risk Assessment Battery. The scale's range goes from 0 to 22. Higher score represents greater frequency of drug risk behaviors
Outcome measures
| Measure |
Methadone Plus Patient Navigation
n=75 Participants
Participants will begin methadone treatment during detention and will have a patient navigator for up to 3 months post-release from detention.
Methadone: Interim methadone treatment (methadone without routine counseling) will be provided in jail. Methadone treatment with counseling will be continued in the community.
Patient Navigation: A patient navigator will assist the participant for the first three months after release from jail to enter and remain in methadone treatment in the community.
|
Methadone
n=74 Participants
Participants will begin methadone during detention.
Methadone: Interim methadone treatment (methadone without routine counseling) will be provided in jail. Methadone treatment with counseling will be continued in the community.
|
Enhanced Treatment as Usual
n=76 Participants
Participants will receive opioid detoxification during detention, as well as drug abuse education, overdose prevention education, and referral to drug abuse treatment and overdose prevention services in the community.
Enhanced Treatment as Usual (ETAU): Participants will receive methadone detoxification, drug abuse and overdose prevention information, drug treatment and overdose prevention referral in the community.
|
|---|---|---|---|
|
Drug Risk Score on the Risk Assessment Battery (RAB)
Baseline
|
2.30 score on a scale
Standard Error .57
|
2.43 score on a scale
Standard Error .62
|
3.11 score on a scale
Standard Error .76
|
|
Drug Risk Score on the Risk Assessment Battery (RAB)
6 month post-release from incarceration
|
1.52 score on a scale
Standard Error .52
|
1.81 score on a scale
Standard Error .65
|
2.16 score on a scale
Standard Error .73
|
|
Drug Risk Score on the Risk Assessment Battery (RAB)
12 month post-release
|
.50 score on a scale
Standard Error .25
|
1.35 score on a scale
Standard Error .59
|
1.03 score on a scale
Standard Error .44
|
SECONDARY outcome
Timeframe: Baseline and 6, and 12 months post-release from incarcerationPopulation: The number analyzed at the follow-up points differ due to missing data (e.g., lost to follow-up, people who were incarcerated during the 6 months prior to the interview).
Sex Risk Score on the Risk Assessment Battery (RAB). Higher scores represents greater risk. The score ranges from 0 to 18.
Outcome measures
| Measure |
Methadone Plus Patient Navigation
n=75 Participants
Participants will begin methadone treatment during detention and will have a patient navigator for up to 3 months post-release from detention.
Methadone: Interim methadone treatment (methadone without routine counseling) will be provided in jail. Methadone treatment with counseling will be continued in the community.
Patient Navigation: A patient navigator will assist the participant for the first three months after release from jail to enter and remain in methadone treatment in the community.
|
Methadone
n=74 Participants
Participants will begin methadone during detention.
Methadone: Interim methadone treatment (methadone without routine counseling) will be provided in jail. Methadone treatment with counseling will be continued in the community.
|
Enhanced Treatment as Usual
n=76 Participants
Participants will receive opioid detoxification during detention, as well as drug abuse education, overdose prevention education, and referral to drug abuse treatment and overdose prevention services in the community.
Enhanced Treatment as Usual (ETAU): Participants will receive methadone detoxification, drug abuse and overdose prevention information, drug treatment and overdose prevention referral in the community.
|
|---|---|---|---|
|
Sex Risk Score on the Risk Assessment Battery (RAB)
Baseline
|
4.52 score on a scale
Standard Error .34
|
4.78 score on a scale
Standard Error .35
|
4.68 score on a scale
Standard Error .34
|
|
Sex Risk Score on the Risk Assessment Battery (RAB)
6 months post-release
|
3.93 score on a scale
Standard Error .34
|
3.94 score on a scale
Standard Error .35
|
4.27 score on a scale
Standard Error .36
|
|
Sex Risk Score on the Risk Assessment Battery (RAB)
12 month post-release
|
3.78 score on a scale
Standard Error .36
|
4.61 score on a scale
Standard Error .42
|
4.17 score on a scale
Standard Error .38
|
SECONDARY outcome
Timeframe: 1, 3, 6, and 12 months post-incarcerationPopulation: The number analyzed at the follow-up points differ due to missing data (e.g., lost to follow-up, people who were incarcerated during the 4 weeks prior to the interview).
The score on the Physical Domain Scale of the World Health Organization Quality of Life Scale-BREF (WHOQOL-BREF). The scales range is from 0 to 100. The higher score represents better quality of life.
Outcome measures
| Measure |
Methadone Plus Patient Navigation
n=75 Participants
Participants will begin methadone treatment during detention and will have a patient navigator for up to 3 months post-release from detention.
Methadone: Interim methadone treatment (methadone without routine counseling) will be provided in jail. Methadone treatment with counseling will be continued in the community.
Patient Navigation: A patient navigator will assist the participant for the first three months after release from jail to enter and remain in methadone treatment in the community.
|
Methadone
n=74 Participants
Participants will begin methadone during detention.
Methadone: Interim methadone treatment (methadone without routine counseling) will be provided in jail. Methadone treatment with counseling will be continued in the community.
|
Enhanced Treatment as Usual
n=76 Participants
Participants will receive opioid detoxification during detention, as well as drug abuse education, overdose prevention education, and referral to drug abuse treatment and overdose prevention services in the community.
Enhanced Treatment as Usual (ETAU): Participants will receive methadone detoxification, drug abuse and overdose prevention information, drug treatment and overdose prevention referral in the community.
|
|---|---|---|---|
|
Physical Domain Score on the World Health Organization Quality of Life Scale (WHOQOL-BREF)
6 months post-release from incarceration
|
68.6 score on a scale
Standard Error 3.1
|
66.3 score on a scale
Standard Error 3.2
|
61.2 score on a scale
Standard Error 3.0
|
|
Physical Domain Score on the World Health Organization Quality of Life Scale (WHOQOL-BREF)
Baseline
|
54.6 score on a scale
Standard Error 2.8
|
58.3 score on a scale
Standard Error 3.0
|
57.1 score on a scale
Standard Error 2.8
|
|
Physical Domain Score on the World Health Organization Quality of Life Scale (WHOQOL-BREF)
1 months post-release from incarceration
|
62.8 score on a scale
Standard Error 3.0
|
62.2 score on a scale
Standard Error 3.4
|
68.7 score on a scale
Standard Error 3.4
|
|
Physical Domain Score on the World Health Organization Quality of Life Scale (WHOQOL-BREF)
3 months post-release from incarceration
|
60.3 score on a scale
Standard Error 3.1
|
60.1 score on a scale
Standard Error 3.1
|
67.3 score on a scale
Standard Error 3.2
|
|
Physical Domain Score on the World Health Organization Quality of Life Scale (WHOQOL-BREF)
12 months post-release from incarceration
|
63.1 score on a scale
Standard Error 3.0
|
63.8 score on a scale
Standard Error 3.2
|
60.3 score on a scale
Standard Error 3.0
|
SECONDARY outcome
Timeframe: 1, 3, 6, and 12 months post-release from incarcerationPopulation: The number analyzed at the follow-up points differ due to missing data (e.g., lost to follow-up, people who were incarcerated during the 4 weeks prior to the interview).
Scale score on the Psychological Domain on the World Health Organization Quality of Life Scale (WHOQOL-BREF) goes from 1 to 100. The higher score represents a better quality of life.
Outcome measures
| Measure |
Methadone Plus Patient Navigation
n=75 Participants
Participants will begin methadone treatment during detention and will have a patient navigator for up to 3 months post-release from detention.
Methadone: Interim methadone treatment (methadone without routine counseling) will be provided in jail. Methadone treatment with counseling will be continued in the community.
Patient Navigation: A patient navigator will assist the participant for the first three months after release from jail to enter and remain in methadone treatment in the community.
|
Methadone
n=74 Participants
Participants will begin methadone during detention.
Methadone: Interim methadone treatment (methadone without routine counseling) will be provided in jail. Methadone treatment with counseling will be continued in the community.
|
Enhanced Treatment as Usual
n=76 Participants
Participants will receive opioid detoxification during detention, as well as drug abuse education, overdose prevention education, and referral to drug abuse treatment and overdose prevention services in the community.
Enhanced Treatment as Usual (ETAU): Participants will receive methadone detoxification, drug abuse and overdose prevention information, drug treatment and overdose prevention referral in the community.
|
|---|---|---|---|
|
Psychological Domain Score on the World Health Organization Quality of Life Scale (WHOQOL-BREF)
Baseline
|
56.8 score on a scale
Standard Error 2.8
|
56.9 score on a scale
Standard Error 3.0
|
55.9 score on a scale
Standard Error 3.0
|
|
Psychological Domain Score on the World Health Organization Quality of Life Scale (WHOQOL-BREF)
1 month post-release from incarceration
|
65.5 score on a scale
Standard Error 3.1
|
64.0 score on a scale
Standard Error 3.5
|
66.7 score on a scale
Standard Error 3.5
|
|
Psychological Domain Score on the World Health Organization Quality of Life Scale (WHOQOL-BREF)
3 months post-release from incarceration
|
62.6 score on a scale
Standard Error 3.4
|
61.2 score on a scale
Standard Error 3.3
|
66.6 score on a scale
Standard Error 3.4
|
|
Psychological Domain Score on the World Health Organization Quality of Life Scale (WHOQOL-BREF)
6 months post-release from incarceration
|
64.9 score on a scale
Standard Error 3.5
|
63.9 score on a scale
Standard Error 3.6
|
64.8 score on a scale
Standard Error 3.4
|
|
Psychological Domain Score on the World Health Organization Quality of Life Scale (WHOQOL-BREF)
12 months post-release from incarceration
|
62.0 score on a scale
Standard Error 3.2
|
61.8 score on a scale
Standard Error 3.4
|
64.4 score on a scale
Standard Error 3.3
|
SECONDARY outcome
Timeframe: 1, 3, 6, and 12 month post-release from incarcerationPopulation: The number analyzed at the follow-up points differ due to missing data (e.g., lost to follow-up, people who were incarcerated during the 4 weeks prior to the interview).
Social domain scale score on the World Health Organization Quality of Life Scale (WHOQOL-BREF) goes from 1 to 100. The higher score represents a better quality of life.
Outcome measures
| Measure |
Methadone Plus Patient Navigation
n=75 Participants
Participants will begin methadone treatment during detention and will have a patient navigator for up to 3 months post-release from detention.
Methadone: Interim methadone treatment (methadone without routine counseling) will be provided in jail. Methadone treatment with counseling will be continued in the community.
Patient Navigation: A patient navigator will assist the participant for the first three months after release from jail to enter and remain in methadone treatment in the community.
|
Methadone
n=74 Participants
Participants will begin methadone during detention.
Methadone: Interim methadone treatment (methadone without routine counseling) will be provided in jail. Methadone treatment with counseling will be continued in the community.
|
Enhanced Treatment as Usual
n=76 Participants
Participants will receive opioid detoxification during detention, as well as drug abuse education, overdose prevention education, and referral to drug abuse treatment and overdose prevention services in the community.
Enhanced Treatment as Usual (ETAU): Participants will receive methadone detoxification, drug abuse and overdose prevention information, drug treatment and overdose prevention referral in the community.
|
|---|---|---|---|
|
Social Domain Score on the World Health Organization Quality of Life Scale (WHOQOL-BREF)
1 month post-release from incarceration
|
63.6 score on a scale
Standard Error 3.9
|
57.5 score on a scale
Standard Error 4.4
|
64.9 score on a scale
Standard Error 4.4
|
|
Social Domain Score on the World Health Organization Quality of Life Scale (WHOQOL-BREF)
Baseline
|
56.9 score on a scale
Standard Error 3.9
|
57.7 score on a scale
Standard Error 4.0
|
51.3 score on a scale
Standard Error 3.9
|
|
Social Domain Score on the World Health Organization Quality of Life Scale (WHOQOL-BREF)
3 months post-release from incarceration
|
60.9 score on a scale
Standard Error 4.1
|
62.4 score on a scale
Standard Error 4.0
|
66.4 score on a scale
Standard Error 4.1
|
|
Social Domain Score on the World Health Organization Quality of Life Scale (WHOQOL-BREF)
6 months post-release from incarceration
|
63.3 score on a scale
Standard Error 3.8
|
63.3 score on a scale
Standard Error 3.9
|
58.8 score on a scale
Standard Error 3.7
|
|
Social Domain Score on the World Health Organization Quality of Life Scale (WHOQOL-BREF)
12 months post-release from incarceration
|
56.6 score on a scale
Standard Error 4.3
|
55.4 score on a scale
Standard Error 4.5
|
59.1 score on a scale
Standard Error 4.3
|
SECONDARY outcome
Timeframe: 1, 3, 6, and 12 months post-release from incarcerationPopulation: The number analyzed at the follow-up points differ due to missing data (e.g., lost to follow-up, people who were incarcerated during the 4 weeks prior to the interview).
Environmental domain score on the World Health Organization Quality of Life Scale (WHOQOL-BREF) goes from 1 to 100. A higher score represents a better quality of life.
Outcome measures
| Measure |
Methadone Plus Patient Navigation
n=75 Participants
Participants will begin methadone treatment during detention and will have a patient navigator for up to 3 months post-release from detention.
Methadone: Interim methadone treatment (methadone without routine counseling) will be provided in jail. Methadone treatment with counseling will be continued in the community.
Patient Navigation: A patient navigator will assist the participant for the first three months after release from jail to enter and remain in methadone treatment in the community.
|
Methadone
n=74 Participants
Participants will begin methadone during detention.
Methadone: Interim methadone treatment (methadone without routine counseling) will be provided in jail. Methadone treatment with counseling will be continued in the community.
|
Enhanced Treatment as Usual
n=76 Participants
Participants will receive opioid detoxification during detention, as well as drug abuse education, overdose prevention education, and referral to drug abuse treatment and overdose prevention services in the community.
Enhanced Treatment as Usual (ETAU): Participants will receive methadone detoxification, drug abuse and overdose prevention information, drug treatment and overdose prevention referral in the community.
|
|---|---|---|---|
|
Environmental Domain Score on the World Health Organization Quality of Life Scale (WHOQOL-BREF)
Baseline
|
48.0 score on a scale
Standard Error 3.0
|
54.6 score on a scale
Standard Error 3.1
|
54.9 score on a scale
Standard Error 3.0
|
|
Environmental Domain Score on the World Health Organization Quality of Life Scale (WHOQOL-BREF)
1 months post-release from incarceration
|
56.1 score on a scale
Standard Error 2.9
|
63.6 score on a scale
Standard Error 3.3
|
65.1 score on a scale
Standard Error 3.3
|
|
Environmental Domain Score on the World Health Organization Quality of Life Scale (WHOQOL-BREF)
3 months post-release from incarceration
|
51.9 score on a scale
Standard Error 3.2
|
55.1 score on a scale
Standard Error 3.2
|
63.7 score on a scale
Standard Error 3.3
|
|
Environmental Domain Score on the World Health Organization Quality of Life Scale (WHOQOL-BREF)
6 months post-release from incarceration
|
59.0 score on a scale
Standard Error 3.3
|
60.6 score on a scale
Standard Error 3.4
|
57.2 score on a scale
Standard Error 3.2
|
|
Environmental Domain Score on the World Health Organization Quality of Life Scale (WHOQOL-BREF)
12 months post-release from incarceration
|
54.8 score on a scale
Standard Error 3.2
|
59.4 score on a scale
Standard Error 3.4
|
59.3 score on a scale
Standard Error 3.3
|
SECONDARY outcome
Timeframe: 1, 3, 6, and 12 month post-release from incarcerationPopulation: The number analyzed at the follow-up points differ due to missing data (e.g., lost to follow-up, people who were incarcerated during the 4 weeks prior to the interview).
Self report quality of life as reported by participants following release from their index incarceration on a scale from 1 to 5. A higher score is a better outcome.
Outcome measures
| Measure |
Methadone Plus Patient Navigation
n=75 Participants
Participants will begin methadone treatment during detention and will have a patient navigator for up to 3 months post-release from detention.
Methadone: Interim methadone treatment (methadone without routine counseling) will be provided in jail. Methadone treatment with counseling will be continued in the community.
Patient Navigation: A patient navigator will assist the participant for the first three months after release from jail to enter and remain in methadone treatment in the community.
|
Methadone
n=74 Participants
Participants will begin methadone during detention.
Methadone: Interim methadone treatment (methadone without routine counseling) will be provided in jail. Methadone treatment with counseling will be continued in the community.
|
Enhanced Treatment as Usual
n=76 Participants
Participants will receive opioid detoxification during detention, as well as drug abuse education, overdose prevention education, and referral to drug abuse treatment and overdose prevention services in the community.
Enhanced Treatment as Usual (ETAU): Participants will receive methadone detoxification, drug abuse and overdose prevention information, drug treatment and overdose prevention referral in the community.
|
|---|---|---|---|
|
Overall Quality of Life Score on the World Health Organization Quality of Life Scale (WHOQOL-BREF)
Baseline
|
2.7 units on a scale
Standard Error 1.6
|
2.8 units on a scale
Standard Error .16
|
3.1 units on a scale
Standard Error .16
|
|
Overall Quality of Life Score on the World Health Organization Quality of Life Scale (WHOQOL-BREF)
1 month post-release from incarceration
|
3.49 units on a scale
Standard Error .162
|
3.56 units on a scale
Standard Error .19
|
3.40 units on a scale
Standard Error .19
|
|
Overall Quality of Life Score on the World Health Organization Quality of Life Scale (WHOQOL-BREF)
3 months post-release from incarceration
|
3.15 units on a scale
Standard Error .17
|
3.46 units on a scale
Standard Error .17
|
3.57 units on a scale
Standard Error .17
|
|
Overall Quality of Life Score on the World Health Organization Quality of Life Scale (WHOQOL-BREF)
6 months post-release from incarceration
|
3.51 units on a scale
Standard Error .17
|
3.58 units on a scale
Standard Error .18
|
3.53 units on a scale
Standard Error .17
|
|
Overall Quality of Life Score on the World Health Organization Quality of Life Scale (WHOQOL-BREF)
12 months post-release from incarceration
|
3.29 units on a scale
Standard Error .17
|
3.43 units on a scale
Standard Error .18
|
3.45 units on a scale
Standard Error .17
|
SECONDARY outcome
Timeframe: 12 months post-release from incarcerationPopulation: Participants who had completed at least one follow-up interview.
Predicted Probability derived from the Generalized Linear Mixed of self-reported enrolled in treatment for Opioid Use Disorder at the time of the follow-up interview (0=not enrolled; 1=enrolled).
Outcome measures
| Measure |
Methadone Plus Patient Navigation
n=69 Participants
Participants will begin methadone treatment during detention and will have a patient navigator for up to 3 months post-release from detention.
Methadone: Interim methadone treatment (methadone without routine counseling) will be provided in jail. Methadone treatment with counseling will be continued in the community.
Patient Navigation: A patient navigator will assist the participant for the first three months after release from jail to enter and remain in methadone treatment in the community.
|
Methadone
n=70 Participants
Participants will begin methadone during detention.
Methadone: Interim methadone treatment (methadone without routine counseling) will be provided in jail. Methadone treatment with counseling will be continued in the community.
|
Enhanced Treatment as Usual
n=70 Participants
Participants will receive opioid detoxification during detention, as well as drug abuse education, overdose prevention education, and referral to drug abuse treatment and overdose prevention services in the community.
Enhanced Treatment as Usual (ETAU): Participants will receive methadone detoxification, drug abuse and overdose prevention information, drug treatment and overdose prevention referral in the community.
|
|---|---|---|---|
|
Predicted Probability Derived From the Generalized Linear Mixed Model of Being Retained in Treatment for Opioid Use Disorder on the Methadone Treatment Exposure Form
1 month post-release from incarceration
|
.63 Probability
Standard Error .08
|
.56 Probability
Standard Error .09
|
.26 Probability
Standard Error .08
|
|
Predicted Probability Derived From the Generalized Linear Mixed Model of Being Retained in Treatment for Opioid Use Disorder on the Methadone Treatment Exposure Form
3 months post-release from incarceration
|
.57 Probability
Standard Error .08
|
.47 Probability
Standard Error .09
|
.19 Probability
Standard Error .07
|
|
Predicted Probability Derived From the Generalized Linear Mixed Model of Being Retained in Treatment for Opioid Use Disorder on the Methadone Treatment Exposure Form
6 months post-release from incarceration
|
.52 Probability
Standard Error .09
|
.52 Probability
Standard Error .09
|
.24 Probability
Standard Error .07
|
|
Predicted Probability Derived From the Generalized Linear Mixed Model of Being Retained in Treatment for Opioid Use Disorder on the Methadone Treatment Exposure Form
12 months post-release from incarceration
|
.40 Probability
Standard Error .09
|
.27 Probability
Standard Error .09
|
.29 Probability
Standard Error .08
|
SECONDARY outcome
Timeframe: 1, 3, 6, and 12 months post-release from incarcerationPopulation: Participants who completed at least one follow-up interview following release from index incarceration
Mean number of days reported by participants of their criminal activity during the 30 days preceding the Addiction Severity Index interviews
Outcome measures
| Measure |
Methadone Plus Patient Navigation
n=75 Participants
Participants will begin methadone treatment during detention and will have a patient navigator for up to 3 months post-release from detention.
Methadone: Interim methadone treatment (methadone without routine counseling) will be provided in jail. Methadone treatment with counseling will be continued in the community.
Patient Navigation: A patient navigator will assist the participant for the first three months after release from jail to enter and remain in methadone treatment in the community.
|
Methadone
n=74 Participants
Participants will begin methadone during detention.
Methadone: Interim methadone treatment (methadone without routine counseling) will be provided in jail. Methadone treatment with counseling will be continued in the community.
|
Enhanced Treatment as Usual
n=76 Participants
Participants will receive opioid detoxification during detention, as well as drug abuse education, overdose prevention education, and referral to drug abuse treatment and overdose prevention services in the community.
Enhanced Treatment as Usual (ETAU): Participants will receive methadone detoxification, drug abuse and overdose prevention information, drug treatment and overdose prevention referral in the community.
|
|---|---|---|---|
|
Mean Number of Days of Criminal Activity in the Past 30 Days Reported by Participants on the Addiction Severity Index (ASI)
1 month post-release from incarceration
|
5.22 Days
Standard Error 1.29
|
8.18 Days
Standard Error 1.74
|
8.22 Days
Standard Error 2.15
|
|
Mean Number of Days of Criminal Activity in the Past 30 Days Reported by Participants on the Addiction Severity Index (ASI)
3 months post-release from incarceration
|
9.79 Days
Standard Error 1.81
|
9.35 Days
Standard Error 1.66
|
10.59 Days
Standard Error 2.15
|
|
Mean Number of Days of Criminal Activity in the Past 30 Days Reported by Participants on the Addiction Severity Index (ASI)
6 months post-release from incarceration
|
9.24 Days
Standard Error 1.88
|
9.74 Days
Standard Error 1.89
|
11.49 Days
Standard Error 1.99
|
|
Mean Number of Days of Criminal Activity in the Past 30 Days Reported by Participants on the Addiction Severity Index (ASI)
12 months post-release from incarceration
|
6.88 Days
Standard Error 1.54
|
9.97 Days
Standard Error 1.88
|
10.18 Days
Standard Error 1.99
|
SECONDARY outcome
Timeframe: 1, 3, 6, and 12 months post-release from incarcerationPopulation: Participants who were interviewed at least once following release from index incarceration.
Mean number of participant self-reported days of heroin use in the 30 days preceding the interview on the Addiction Severity Index (ASI)
Outcome measures
| Measure |
Methadone Plus Patient Navigation
n=75 Participants
Participants will begin methadone treatment during detention and will have a patient navigator for up to 3 months post-release from detention.
Methadone: Interim methadone treatment (methadone without routine counseling) will be provided in jail. Methadone treatment with counseling will be continued in the community.
Patient Navigation: A patient navigator will assist the participant for the first three months after release from jail to enter and remain in methadone treatment in the community.
|
Methadone
n=74 Participants
Participants will begin methadone during detention.
Methadone: Interim methadone treatment (methadone without routine counseling) will be provided in jail. Methadone treatment with counseling will be continued in the community.
|
Enhanced Treatment as Usual
n=76 Participants
Participants will receive opioid detoxification during detention, as well as drug abuse education, overdose prevention education, and referral to drug abuse treatment and overdose prevention services in the community.
Enhanced Treatment as Usual (ETAU): Participants will receive methadone detoxification, drug abuse and overdose prevention information, drug treatment and overdose prevention referral in the community.
|
|---|---|---|---|
|
Mean Number of Days of Illicit Opioid Use Reported by Participants in the Past 30 Days
1 month post-release from incarceration
|
8.66 Days
Standard Error 1.32
|
12.07 Days
Standard Error 1.72
|
14.88 Days
Standard Error 2.12
|
|
Mean Number of Days of Illicit Opioid Use Reported by Participants in the Past 30 Days
3 months post-release from incarceration
|
13.46 Days
Standard Error 1.84
|
15.15 Days
Standard Error 1.84
|
16.18 Days
Standard Error 2.04
|
|
Mean Number of Days of Illicit Opioid Use Reported by Participants in the Past 30 Days
6 months post-release from incarceration
|
13.56 Days
Standard Error 1.83
|
14.02 Days
Standard Error 1.90
|
15.42 Days
Standard Error 1.90
|
|
Mean Number of Days of Illicit Opioid Use Reported by Participants in the Past 30 Days
12 months post-release from incarceration
|
12.35 Days
Standard Error 1.66
|
14.70 Days
Standard Error 1.82
|
15.35 Days
Standard Error 1.90
|
SECONDARY outcome
Timeframe: 1, 3, 6, and 12 months post-release from incarcerationPopulation: Participants who were interviewed at least once following release from index incarceration
Participant self-reported mean number of days of cocaine use in the 30 days preceding the interview on the Addiction Severity Index (ASI)
Outcome measures
| Measure |
Methadone Plus Patient Navigation
n=75 Participants
Participants will begin methadone treatment during detention and will have a patient navigator for up to 3 months post-release from detention.
Methadone: Interim methadone treatment (methadone without routine counseling) will be provided in jail. Methadone treatment with counseling will be continued in the community.
Patient Navigation: A patient navigator will assist the participant for the first three months after release from jail to enter and remain in methadone treatment in the community.
|
Methadone
n=74 Participants
Participants will begin methadone during detention.
Methadone: Interim methadone treatment (methadone without routine counseling) will be provided in jail. Methadone treatment with counseling will be continued in the community.
|
Enhanced Treatment as Usual
n=76 Participants
Participants will receive opioid detoxification during detention, as well as drug abuse education, overdose prevention education, and referral to drug abuse treatment and overdose prevention services in the community.
Enhanced Treatment as Usual (ETAU): Participants will receive methadone detoxification, drug abuse and overdose prevention information, drug treatment and overdose prevention referral in the community.
|
|---|---|---|---|
|
Participant Self-reported Mean Number of Days of Cocaine Use in the Past 30 Days
1 month post-release from incarceration
|
5.95 Days
Standard Error 1.29
|
9.05 Days
Standard Error 1.73
|
11.01 Days
Standard Error 2.10
|
|
Participant Self-reported Mean Number of Days of Cocaine Use in the Past 30 Days
3 months post-release from incarceration
|
8.83 Days
Standard Error 1.71
|
11.32 Days
Standard Error 1.93
|
11.94 Days
Standard Error 2.14
|
|
Participant Self-reported Mean Number of Days of Cocaine Use in the Past 30 Days
6 months post-release from incarceration
|
10.74 Days
Standard Error 1.86
|
13.57 Days
Standard Error 2.23
|
11.94 Days
Standard Error 2.14
|
|
Participant Self-reported Mean Number of Days of Cocaine Use in the Past 30 Days
12 months post-release from incarceration
|
9.60 Days
Standard Error 1.70
|
14.46 Days
Standard Error 2.19
|
12.63 Days
Standard Error 2.01
|
SECONDARY outcome
Timeframe: 3, 6, and 12 months post-release from incarcerationPopulation: Participants who completed at least one interview following release from index incarceration
Predicted Probability Derived from the Generalized Linear Mixed Model meeting Data and Statistical Manual - 5 criteria for Cocaine Use Disorder on the modified Composite International Diagnostic Interview (CIDI) (0=Does not meet criteria; 1=meets criteria).
Outcome measures
| Measure |
Methadone Plus Patient Navigation
n=75 Participants
Participants will begin methadone treatment during detention and will have a patient navigator for up to 3 months post-release from detention.
Methadone: Interim methadone treatment (methadone without routine counseling) will be provided in jail. Methadone treatment with counseling will be continued in the community.
Patient Navigation: A patient navigator will assist the participant for the first three months after release from jail to enter and remain in methadone treatment in the community.
|
Methadone
n=74 Participants
Participants will begin methadone during detention.
Methadone: Interim methadone treatment (methadone without routine counseling) will be provided in jail. Methadone treatment with counseling will be continued in the community.
|
Enhanced Treatment as Usual
n=76 Participants
Participants will receive opioid detoxification during detention, as well as drug abuse education, overdose prevention education, and referral to drug abuse treatment and overdose prevention services in the community.
Enhanced Treatment as Usual (ETAU): Participants will receive methadone detoxification, drug abuse and overdose prevention information, drug treatment and overdose prevention referral in the community.
|
|---|---|---|---|
|
Predicted Probability Derived From the Generalized Linear Mixed Model of Meeting Cocaine Use Disorder Criteria in the Past 30 Days
12 months post-release from incarceration
|
.32 Probability
Standard Error .15
|
.40 Probability
Standard Error .20
|
.30 Probability
Standard Error .14
|
|
Predicted Probability Derived From the Generalized Linear Mixed Model of Meeting Cocaine Use Disorder Criteria in the Past 30 Days
3 months post-release from incarceration
|
.20 Probability
Standard Error .08
|
.32 Probability
Standard Error .011
|
.32 Probability
Standard Error .12
|
|
Predicted Probability Derived From the Generalized Linear Mixed Model of Meeting Cocaine Use Disorder Criteria in the Past 30 Days
6 months post-release from incarceration
|
.22 Probability
Standard Error .10
|
.35 Probability
Standard Error .12
|
.36 Probability
Standard Error .14
|
SECONDARY outcome
Timeframe: 12 months post-release from incarcerationMean number of days hospitalized during the 12 months post-release from incarceration
Outcome measures
| Measure |
Methadone Plus Patient Navigation
n=67 Participants
Participants will begin methadone treatment during detention and will have a patient navigator for up to 3 months post-release from detention.
Methadone: Interim methadone treatment (methadone without routine counseling) will be provided in jail. Methadone treatment with counseling will be continued in the community.
Patient Navigation: A patient navigator will assist the participant for the first three months after release from jail to enter and remain in methadone treatment in the community.
|
Methadone
n=67 Participants
Participants will begin methadone during detention.
Methadone: Interim methadone treatment (methadone without routine counseling) will be provided in jail. Methadone treatment with counseling will be continued in the community.
|
Enhanced Treatment as Usual
n=58 Participants
Participants will receive opioid detoxification during detention, as well as drug abuse education, overdose prevention education, and referral to drug abuse treatment and overdose prevention services in the community.
Enhanced Treatment as Usual (ETAU): Participants will receive methadone detoxification, drug abuse and overdose prevention information, drug treatment and overdose prevention referral in the community.
|
|---|---|---|---|
|
Days of Hospitalization (Health Care Utilization) on the Economic Form 90 (EF-90)
|
2.0 Days
Standard Deviation 5.8
|
3.4 Days
Standard Deviation 9.7
|
1.2 Days
Standard Deviation 3.1
|
SECONDARY outcome
Timeframe: 12 months post-release from incarcerationCost in US Dollars of substance abuse services on the modified Substance Abuse Services Cost Analysis Program
Outcome measures
| Measure |
Methadone Plus Patient Navigation
n=68 Participants
Participants will begin methadone treatment during detention and will have a patient navigator for up to 3 months post-release from detention.
Methadone: Interim methadone treatment (methadone without routine counseling) will be provided in jail. Methadone treatment with counseling will be continued in the community.
Patient Navigation: A patient navigator will assist the participant for the first three months after release from jail to enter and remain in methadone treatment in the community.
|
Methadone
n=68 Participants
Participants will begin methadone during detention.
Methadone: Interim methadone treatment (methadone without routine counseling) will be provided in jail. Methadone treatment with counseling will be continued in the community.
|
Enhanced Treatment as Usual
n=61 Participants
Participants will receive opioid detoxification during detention, as well as drug abuse education, overdose prevention education, and referral to drug abuse treatment and overdose prevention services in the community.
Enhanced Treatment as Usual (ETAU): Participants will receive methadone detoxification, drug abuse and overdose prevention information, drug treatment and overdose prevention referral in the community.
|
|---|---|---|---|
|
Cost of Substance Abuse Services
|
3052 US Dollars
Standard Deviation 533
|
2377 US Dollars
Standard Deviation 351
|
1884 US Dollars
Standard Deviation 292
|
Adverse Events
Methadone Plus Patient Navigation
Serious events: 11 serious events
Other events: 3 other events
Deaths: 1 deaths
Methadone
Serious events: 20 serious events
Other events: 12 other events
Deaths: 3 deaths
Enhanced Treatment as Usual
Serious events: 16 serious events
Other events: 12 other events
Deaths: 3 deaths
Serious adverse events
| Measure |
Methadone Plus Patient Navigation
n=75 participants at risk
Participants will begin methadone treatment during detention and will have a patient navigator for up to 3 months post-release from detention.
Methadone: Interim methadone treatment (methadone without routine counseling) will be provided in jail. Methadone treatment with counseling will be continued in the community.
Patient Navigation: A patient navigator will assist the participant for the first three months after release from jail to enter and remain in methadone treatment in the community.
|
Methadone
n=74 participants at risk
Participants will begin methadone during detention.
Methadone: Interim methadone treatment (methadone without routine counseling) will be provided in jail. Methadone treatment with counseling will be continued in the community.
|
Enhanced Treatment as Usual
n=76 participants at risk
Participants will receive opioid detoxification during detention, as well as drug abuse education, overdose prevention education, and referral to drug abuse treatment and overdose prevention services in the community.
Enhanced Treatment as Usual (ETAU): Participants will receive methadone detoxification, drug abuse and overdose prevention information, drug treatment and overdose prevention referral in the community.
|
|---|---|---|---|
|
Hepatobiliary disorders
Hospitalization
|
0.00%
0/75 • 12 months following release from index incarceration
|
0.00%
0/74 • 12 months following release from index incarceration
|
1.3%
1/76 • Number of events 1 • 12 months following release from index incarceration
|
|
Infections and infestations
Hospitalization
|
2.7%
2/75 • Number of events 3 • 12 months following release from index incarceration
|
9.5%
7/74 • Number of events 10 • 12 months following release from index incarceration
|
5.3%
4/76 • Number of events 8 • 12 months following release from index incarceration
|
|
Injury, poisoning and procedural complications
Hospitalization
|
2.7%
2/75 • Number of events 2 • 12 months following release from index incarceration
|
2.7%
2/74 • Number of events 10 • 12 months following release from index incarceration
|
10.5%
8/76 • Number of events 8 • 12 months following release from index incarceration
|
|
Musculoskeletal and connective tissue disorders
Hospitalization
|
0.00%
0/75 • 12 months following release from index incarceration
|
0.00%
0/74 • 12 months following release from index incarceration
|
1.3%
1/76 • Number of events 1 • 12 months following release from index incarceration
|
|
Psychiatric disorders
Hospitalization
|
1.3%
1/75 • Number of events 1 • 12 months following release from index incarceration
|
5.4%
4/74 • Number of events 7 • 12 months following release from index incarceration
|
1.3%
1/76 • Number of events 1 • 12 months following release from index incarceration
|
|
Respiratory, thoracic and mediastinal disorders
Hospitalization
|
2.7%
2/75 • Number of events 2 • 12 months following release from index incarceration
|
2.7%
2/74 • Number of events 2 • 12 months following release from index incarceration
|
1.3%
1/76 • Number of events 1 • 12 months following release from index incarceration
|
|
Gastrointestinal disorders
Hospitalization
|
0.00%
0/75 • 12 months following release from index incarceration
|
1.4%
1/74 • Number of events 5 • 12 months following release from index incarceration
|
0.00%
0/76 • 12 months following release from index incarceration
|
|
Nervous system disorders
Hospitalization
|
2.7%
2/75 • Number of events 3 • 12 months following release from index incarceration
|
2.7%
2/74 • Number of events 2 • 12 months following release from index incarceration
|
0.00%
0/76 • 12 months following release from index incarceration
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hospitalization
|
0.00%
0/75 • 12 months following release from index incarceration
|
1.4%
1/74 • Number of events 1 • 12 months following release from index incarceration
|
0.00%
0/76 • 12 months following release from index incarceration
|
|
Vascular disorders
Hospitalization
|
1.3%
1/75 • Number of events 1 • 12 months following release from index incarceration
|
2.7%
2/74 • Number of events 2 • 12 months following release from index incarceration
|
0.00%
0/76 • 12 months following release from index incarceration
|
|
Blood and lymphatic system disorders
Hospitalization
|
2.7%
2/75 • Number of events 2 • 12 months following release from index incarceration
|
0.00%
0/74 • 12 months following release from index incarceration
|
0.00%
0/76 • 12 months following release from index incarceration
|
|
Cardiac disorders
Hospitalization
|
2.7%
2/75 • Number of events 4 • 12 months following release from index incarceration
|
0.00%
0/74 • 12 months following release from index incarceration
|
0.00%
0/76 • 12 months following release from index incarceration
|
|
Metabolism and nutrition disorders
Hospitalization
|
1.3%
1/75 • Number of events 1 • 12 months following release from index incarceration
|
0.00%
0/74 • 12 months following release from index incarceration
|
0.00%
0/76 • 12 months following release from index incarceration
|
Other adverse events
| Measure |
Methadone Plus Patient Navigation
n=75 participants at risk
Participants will begin methadone treatment during detention and will have a patient navigator for up to 3 months post-release from detention.
Methadone: Interim methadone treatment (methadone without routine counseling) will be provided in jail. Methadone treatment with counseling will be continued in the community.
Patient Navigation: A patient navigator will assist the participant for the first three months after release from jail to enter and remain in methadone treatment in the community.
|
Methadone
n=74 participants at risk
Participants will begin methadone during detention.
Methadone: Interim methadone treatment (methadone without routine counseling) will be provided in jail. Methadone treatment with counseling will be continued in the community.
|
Enhanced Treatment as Usual
n=76 participants at risk
Participants will receive opioid detoxification during detention, as well as drug abuse education, overdose prevention education, and referral to drug abuse treatment and overdose prevention services in the community.
Enhanced Treatment as Usual (ETAU): Participants will receive methadone detoxification, drug abuse and overdose prevention information, drug treatment and overdose prevention referral in the community.
|
|---|---|---|---|
|
Injury, poisoning and procedural complications
Non fatal overdose
|
4.0%
3/75 • 12 months following release from index incarceration
|
16.2%
12/74 • 12 months following release from index incarceration
|
15.8%
12/76 • 12 months following release from index incarceration
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place